New lupus drug enters early human testing

NCT ID NCT06625671

Recruiting now Disease control Sponsor: DualityBio Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial is testing a new drug called DB-2304 in healthy volunteers and people with lupus (SLE or CLE). The main goal is to check safety and how the body processes the drug. About 148 participants will receive either DB-2304 or a placebo. This is a first step to see if the drug is safe enough for larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DB-2304
What this could lead to: If it works, this could point toward a new treatment option for lupus that helps control the disease.
What could go wrong: This is a very early, small trial focused on safety and dosing. It is not designed to prove effectiveness, and many early-stage drugs fail to show benefit in later studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous lupus erythematosus lupus erythematosus systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) OR CUTANEOUS LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

Site AUS01-0
COMPLETED

Melbourne, Victoria, 3004, Australia
US02-0
RECRUITING

San Antonio, Texas, 78215, United States
US03-0
RECRUITING

Clearwater, Florida, 33765, United States
US04-0
RECRUITING

Irving, Texas, 75061, United States
US05-0
RECRUITING

Orlando, Florida, 32808, United States
US06-0
RECRUITING

La Palma, California, 90623, United States
US08-0
NOT_YET_RECRUITING

Syracuse, New York, 13210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.